← Leaderboards
Kenneth Hugh Pearce
Univ Of North Carolina Chapel Hill
$13,826,383
Attributed
$18,481,599
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.8M · FY2015–24$20M$15M$10M$5M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$18,481,599 · 6
By mechanism
U19$9,381,848 · 1
R01$7,587,953 · 4
R56$1,511,798 · 1
Top collaborators
- Cyrus Vaziri11 shared
- John E Sondek6 shared
- Qisheng Zhang6 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Cyrus Vaziri$12,585,722
- Dirk P Dittmer$32,603,888
- John E Sondek$15,232,788
- Qisheng Zhang$4,632,517
- Sang-Hoon Sin$525,632
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseStructureProteinsSignal TransductionMalignant NeoplasmsScreeningLibrariesBindingCellsTherapeutic AgentsCellular AssayToxic EffectPathway InteractionsNew Therapeutic TargetMolecularGenesPathologicSide EffectDrug DiscoveryLeadInnovationCancer CellCause Of DeathEngineering
Grant awards (21)
Discovery of allosteric activators of phospholipase C-gamma2 to treat Alzheimer's disease$748,573
R56 · FY2024 · AG
A high-throughput platform to identify selective allosteric inhibitors of the PLC-y isozymes$508,118
R01 · FY2024 · CA
Discovery of allosteric activators of phospholipase C-gamma2 to treat Alzheimer's disease$763,225
R56 · FY2023 · AG
A high-throughput platform to identify selective allosteric inhibitors of the PLC-y isozymes$536,812
R01 · FY2023 · CA
Pathological Reprogramming of DNA Damage Signaling in Neoplastic Cells$463,301
R01 · FY2023 · ES
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target$391,466
R01 · FY2023 · CA
Core B: Discovery Core$9,381,848
U19 · FY2022 · AI · contact PI
A high-throughput platform to identify selective allosteric inhibitors of the PLC-y isozymes$583,609
R01 · FY2022 · CA
Pathological Reprogramming of DNA Damage Signaling in Neoplastic Cells$463,301
R01 · FY2022 · ES
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target$344,451
R01 · FY2022 · CA
A high-throughput platform to identify selective allosteric inhibitors of the PLC-y isozymes$569,708
R01 · FY2021 · CA
Pathological Reprogramming of DNA Damage Signaling in Neoplastic Cells$463,301
R01 · FY2021 · ES
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target$402,605
R01 · FY2021 · CA
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target$80,061
R01 · FY2021 · CA
Pathological Reprogramming of DNA Damage Signaling in Neoplastic Cells$467,927
R01 · FY2020 · ES
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target$403,864
R01 · FY2020 · CA
Pathological Reprogramming of DNA Damage Signaling in Neoplastic Cells$469,870
R01 · FY2019 · ES
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target$413,559
R01 · FY2019 · CA
High Throughput Screening Assay for IP7K inositol pyrophosphate kinases$342,000
R01 · FY2017 · DK · contact PI
High Throughput Screening Assay for IP7K inositol pyrophosphate kinases$342,000
R01 · FY2016 · DK · contact PI
High Throughput Screening Assay for IP7K inositol pyrophosphate kinases$342,000
R01 · FY2015 · DK · contact PI